Amgen Announces CFO Retirement and Successor Appointment

SEC 8-K Filing Notice

Company: Amgen Inc. (AMGN) Filing Date: 2026-05-19 Accession Number: 0000318154-26-000097

Items Filed

Item 5.02: Departure of Directors or Certain Officers; Election of Directors

Summary

Amgen (AMGN) announced the retirement of Executive Vice President and Chief Financial Officer, Peter H. Griffith, effective August 31, 2026. He will transition to a non-executive role until January 31, 2027, before fully retiring. Simultaneously, the company announced the appointment of Thomas Dittrich as the new Executive Vice President and Chief Financial Officer, effective September 1, 2026. Dittrich, age 62, will initially be based in Switzerland before relocating to Amgen's headquarters in Thousand Oaks, California. He brings extensive experience, including previous CFO roles at Galderma Group AG and Shire Pharmaceuticals.

Key Takeaways

Peter H. Griffith to retire as Amgen's CFO on August 31, 2026, transitioning to a non-executive role until January 2027.
Thomas Dittrich appointed as the new Executive Vice President and CFO, effective September 1, 2026.
Dittrich's compensation package includes a CHF 1,070,000 annual base salary, participation in the Global Management Incentive Plan, and long-term equity compensation.
Amgen is providing Dittrich with significant compensation to offset foregone equity and incentives from his previous employer, including a one-time RSU award and a cash bonus.
Dittrich has a strong background in finance and leadership roles within the pharmaceutical and related industries.

Analysis

The change in CFO represents a significant leadership transition for Amgen. Investors will likely scrutinize Dittrich's performance and strategic decisions as he assumes the CFO role. His prior experience with Shire Pharmaceuticals, particularly during its acquisition by Takeda, could be valuable as Amgen navigates the evolving pharmaceutical landscape. The substantial compensation package offered to Dittrich reflects the competitive market for top-tier financial executives and Amgen's commitment to securing experienced leadership. Competitors will be watching to see if this change impacts Amgen's financial strategy and performance.

This post was automatically generated from an SEC 8-K filing.